Last reviewed · How we verify
NCT05165212
Primary Care Amoxicillin Challenge
Phase 4 trial testing Amoxicillin in Amoxicillin Allergy. Withdrawn.
31 December 2025
Quick facts
| Lead sponsor | State University of New York at Buffalo |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Start date | 31 December 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 1 January 2026 |
Drugs / interventions tested
- Amoxicillin (amoxicillin) — full drug profile →
Conditions studied
- Amoxicillin Allergy — all drugs for Amoxicillin Allergy →
Sponsor
State University of New York at Buffalo
Who can join
Under 17, any sex, with Amoxicillin Allergy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this project is to identify clinic patients reporting penicillin allergy who are low risk for allergic reaction, and then invite them to participate in an oral amoxicillin challenge in their primary office without need for referral to allergy/immunology. If the patient is able to tolerate oral amoxicillin, the antibiotic allergy in question will be removed from the patient's chart.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05165212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Amoxicillin
Trials testing the same drug.
- NCT07457385 — Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates · Phase 4 · not yet recruiting
- NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
- NCT07293910 — Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Py · Phase 2 · recruiting
- NCT06921213 — Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis · Phase 2 · not yet recruiting
- NCT06869850 — Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition · NA · recruiting
Other recruiting trials for Amoxicillin Allergy
Currently open trials in the same condition.
- NCT06409884 — Diagnosing Drug Allergy: the T is the Key · NA · recruiting
Other State University of New York at Buffalo trials
Trials by the same sponsor.
- NCT07072767 — Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation · NA · not yet recruiting
- NCT07140848 — CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes · NA · not yet recruiting
- NCT07433959 — Neuromodulation to Improve Grasping Function After SCI · NA · not yet recruiting
- NCT07403539 — Speech Learning and Speech Production in Parkinson's Disease · NA · recruiting
- NCT05367362 — Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05165212 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by State University of New York at Buffalo
- Last refreshed: 18 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05165212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing